摘要
對colistin抗藥的carbapenem-resistant Klebsiella pneumoniae（CRKP）由於治療選擇有限，在臨床上帶來很大的挑戰。CRKP對colistin抗藥的比例近10年在許多地區明顯上升，而多種抗生素的使用被發現是其危險因子。CRKP對colistin產生抗藥性的分子機轉牽涉到多重基因的調控，其中mgrB基因的變異是最常見的機轉。目前臨床上處理colistin抗藥的CRKP能選擇的抗生素相當有限，tigecyline、aminoglycosides、fosfomycin各自有其成效、劑量，或安全性的疑慮。雖然有其他治療CRKP的新藥已被研發，目前臺灣只有ceftazidime-avibactam已經上市。
參考文獻
Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, et al. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clin Microbiol Rev 2018;31:e00079-17.
Laura J Rojas, Madiha Salim, Eric Cober, et al. Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality. Clin Infect Dis 2017;64:711-8.
Poirel L, Jayol A, Nordmann P. Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes. Clin Microbiol Rev 2017;30:557-96.
Giani T, Arena F, Vaggelli G, et al. Large Nosocomial Outbreak of Colistin-Resistant, Carbapenemase-Producing Klebsiella pneumoniae Traced to Clonal Expansion of an mgrB Deletion Mutant. J Clin Microbiol 2015;3:3341-4.
Lai CC, Chen YS, Lee NY, et al. Susceptibility rates of clinically important bacteria collected from intensive care units against colistin, carbapenems, and other comparative agents: results from Surveillance of Multicenter Antimicrobial Resistance in Taiwan(SMART). Infect Drug Resist 2019;12:627-40.